{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:23:26Z","timestamp":1793391806964,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T00:00:00Z","timestamp":1498176000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005918","name":"Christian Medical College, Vellore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005918","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s10067-017-3726-2","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T12:11:57Z","timestamp":1498219917000},"page":"2243-2251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["TNF\u03b1 blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis"],"prefix":"10.1007","volume":"36","author":[{"given":"Aswin M.","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sandhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijesh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashish","family":"Danda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,23]]},"reference":[{"issue":"3","key":"3726_CR1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.berh.2006.02.001","volume":"20","author":"J Sieper","year":"2006","unstructured":"Sieper J, Rudwaleit M, Khan MA, Braun J (2006 Jun) Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 20(3):401\u2013417","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"3726_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ard.2010.135889","volume":"70","author":"H Zeidler","year":"2011","unstructured":"Zeidler H, Amor B (2011 Jan) The assessment in spondyloarthritis international society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress. Ann Rheum Dis 70(1):1\u20133","journal-title":"Ann Rheum Dis"},{"key":"3726_CR3","doi-asserted-by":"crossref","unstructured":"Baraliakos X, Berg R van den Braun J, van der Heijde D (2012) Update of the literature review on treatment with biologics as a basis for the first update of the ASAS\/EULAR management recommendations of ankylosing spondylitis. Rheumatology kes026","DOI":"10.1093\/rheumatology\/kes026"},{"key":"3726_CR4","first-page":"CD005468","volume":"4","author":"LJ Maxwell","year":"2015","unstructured":"Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MMS, Tanjong Ghogomu E et al (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD005468","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"3726_CR5","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","volume":"50","author":"X Baraliakos","year":"2011","unstructured":"Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester G-R et al (2011 Sep) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years\u2014early clinical response predicts long-term outcome. Rheumatol Oxf Engl. 50(9):1690\u20131699","journal-title":"Rheumatol Oxf Engl."},{"key":"3726_CR6","unstructured":"P Keith M. Overview of Drug Therapy for Spondyloarthritis. Rheumatol Curr Res [Internet]. 2013 [cited 2016 Aug 31];3(2). Available from: http:\/\/www.omicsonline.org\/overview-of-drug-therapy-for-spondyloarthritis-2161-1149.1000119.php?aid=18720"},{"issue":"2","key":"3726_CR7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s100670050027","volume":"19","author":"D Biasi","year":"2000","unstructured":"Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM (2000) Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 19(2):114\u2013117","journal-title":"Clin Rheumatol"},{"issue":"6","key":"3726_CR8","first-page":"1104","volume":"22","author":"MC Creemers","year":"1995","unstructured":"Creemers MC, Franssen MJ, van de Putte LB, Gribnau FW, van Riel PL (1995 Jun) Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol 22(6):1104\u20131107","journal-title":"J Rheumatol"},{"issue":"5","key":"3726_CR9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/030097401753180318","volume":"30","author":"MY Lale Altan","year":"2001","unstructured":"Lale Altan MY (2001 Jan 1) \u00dcmit Bing\u00f6l, Y\u00dcksel Karako\u00e7, Saadet Ayd\u0131ner, Mustafa Yurtkuran. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 30(5):255\u2013259","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"3726_CR10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/030097400750002021","volume":"29","author":"PD Sampaio-Barros","year":"2000","unstructured":"Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM (2000) Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 29(3):160\u2013162","journal-title":"Scand J Rheumatol"},{"key":"3726_CR11","first-page":"CD004524","volume":"2","author":"J Chen","year":"2013","unstructured":"Chen J, Veras MMS, Liu C, Lin J (2013) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2:CD004524","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"3726_CR12","first-page":"1568","volume":"31","author":"L Gonzalez-Lopez","year":"2004","unstructured":"Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Mu\u00f1oz-Valle JF, Gamez-Nava JI (2004) Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 31(8):1568\u20131574","journal-title":"J Rheumatol"},{"issue":"9","key":"3726_CR13","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/ard.2006.052878","volume":"65","author":"J Braun","year":"2006","unstructured":"Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K et al (2006 Sep) Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 65(9):1147\u20131153","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3726_CR14","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","volume":"42","author":"DO Clegg","year":"1999","unstructured":"Clegg DO, Reda DJ, Abdellatif M (1999 Nov) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42(11):2325\u20132329","journal-title":"Arthritis Rheum"},{"issue":"11","key":"3726_CR15","first-page":"1482","volume":"17","author":"MB Ferraz","year":"1990","unstructured":"Ferraz MB, Tugwell P, Goldsmith CH, Atra E (1990 Nov) Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 17(11):1482\u20131486","journal-title":"J Rheumatol"},{"issue":"6552","key":"3726_CR16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/bmj.293.6552.911","volume":"293","author":"M Dougados","year":"1986","unstructured":"Dougados M, Boumier P, Amor B (1986 Oct 11) Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J Clin Res Ed 293(6552):911\u2013914","journal-title":"Br Med J Clin Res Ed"},{"issue":"6","key":"3726_CR17","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E et al (2011 Jun 1) 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896\u2013904","journal-title":"Ann Rheum Dis"},{"key":"3726_CR18","doi-asserted-by":"crossref","unstructured":"Chen J, Lin S, Liu C (2014) Sulfasalazine for ankylosing spondylitis. In: Cochrane Database of Systematic Reviews [Internet]. John Wiley & Sons, Ltd; [cited 2016 Aug 31]. Available from: http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD004800.pub3\/abstract","DOI":"10.1002\/14651858.CD004800.pub3"},{"issue":"6","key":"3726_CR19","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","volume":"63","author":"J Braun","year":"2011","unstructured":"Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS et al (2011 Jun 1) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63(6):1543\u20131551","journal-title":"Arthritis Rheum"},{"issue":"7","key":"3726_CR20","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s10067-011-1723-4","volume":"30","author":"P Sandhya","year":"2011","unstructured":"Sandhya P, Danda D, Mathew J, Gattani A (2011 Jul) Outcome of patients with seronegative spondyloarthritis continuing sulphasalazine and methotrexate after a short course of infliximab therapy\u2014experience from a tertiary care teaching hospital in South India. Clin Rheumatol 30(7):997\u20131001","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3726_CR21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Akkoc N, Brandt J, Chou CT et al (2011 Jan) The assessment of Spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25\u201331","journal-title":"Ann Rheum Dis"},{"key":"3726_CR22","unstructured":"CDC | TB | Treatment | Treatment Regimens for Latent TB Infection (LTBI) [Internet]. [cited 2017 May 30]. Available from: https:\/\/www.cdc.gov\/tb\/topic\/treatment\/ltbi.htm"},{"issue":"6","key":"3726_CR23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","volume":"74","author":"J Callhoff","year":"2015","unstructured":"Callhoff J, Sieper J, Wei\u00df A, Zink A, Listing J (2015 Jun) Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 74(6):1241\u20131248","journal-title":"Ann Rheum Dis"},{"key":"3726_CR24","doi-asserted-by":"crossref","unstructured":"Ai J-W, Ruan Q-L, Liu Q-H, Zhang W-H (2016, e10) Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect 5","DOI":"10.1038\/emi.2016.10"},{"issue":"3","key":"3726_CR25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1378\/chest.12-0142","volume":"142","author":"SK Sharma","year":"2012","unstructured":"Sharma SK, Mohanan S, Sharma A (2012) Relevance of latent TBinfection in areas of high TB prevalence. Chest 142(3):761\u2013773","journal-title":"Chest"},{"key":"3726_CR26","unstructured":"WHO | Guidelines on the management of latent tuberculosis infection [Internet]. WHO. [cited 2017 Jan 7]. Available from: http:\/\/www.who.int\/tb\/publications\/latent-tuberculosis-infection\/en\/"},{"key":"3726_CR27","volume-title":"Global Tuberculose Report: 2015","author":"Organisation mondiale de la sant\u00e9","year":"2015","unstructured":"Organisation mondiale de la sant\u00e9 (2015) Global Tuberculose Report: 2015. Word Health Organization, Gen\u00e8ve (Suisse)"},{"issue":"12","key":"3726_CR28","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/kel156","volume":"45","author":"RN Jois","year":"2006","unstructured":"Jois RN, Leeder J, Gibb A, Gaffney K, Macgregor A, Somerville M et al (2006 Dec 1) Low-dose infliximab treatment for ankylosing spondylitis\u2014clinically- and cost-effective. Rheumatology 45(12):1566\u20131569","journal-title":"Rheumatology"},{"issue":"4","key":"3726_CR29","first-page":"513","volume":"23","author":"P Sidiropoulos","year":"2005","unstructured":"Sidiropoulos P, Kritikos HD, Siakka P, Mamoulaki M, Kouroumali H, Voudouris K et al (2005) Low-dose of infliximab is inadequate in most patients with spondylarthropathies. Clin Exp Rheumatol 23(4):513","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"3726_CR30","first-page":"558","volume":"33","author":"S Keeling","year":"2006","unstructured":"Keeling S, Oswald A, Russell AS, Maksymowych WP (2006 Mar) Prospective observational analysis of the efficacy and safety of low-dose (3 mg\/kg) infliximab in ankylosing spondylitis: 4-year followup. J Rheumatol 33(3):558\u2013561","journal-title":"J Rheumatol"},{"issue":"2","key":"3726_CR31","doi-asserted-by":"crossref","first-page":"e000272","DOI":"10.1136\/rmdopen-2016-000272","volume":"2","author":"X Baraliakos","year":"2016","unstructured":"Baraliakos X, Heldmann F, van den Bosch F, Burmester G, Gaston H, van der Horst-Bruinsma IE et al (2016) Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. RMD Open 2(2):e000272","journal-title":"RMD Open"},{"issue":"1","key":"3726_CR32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/art.23167","volume":"58","author":"M Breban","year":"2008","unstructured":"Breban M, Ravaud P, Claudepierre P, Baron G, Henry Y-D, Hudry C et al (2008 Jan 1) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58(1):88\u201397","journal-title":"Arthritis Rheum"},{"issue":"7","key":"3726_CR33","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/kel015","volume":"45","author":"L Gossec","year":"2006","unstructured":"Gossec L (2006) Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up. Rheumatology 45(7):859\u2013862","journal-title":"Rheumatology"},{"issue":"7","key":"3726_CR34","first-page":"355","volume":"21","author":"S Sengupta","year":"2015","unstructured":"Sengupta S, Ray J, Ghosh B (2015) Quality of life and clinical response to on-demand maintenance doses of infliximab in patients with ankylosing spondylitis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 21(7):355\u2013358","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"issue":"3","key":"3726_CR35","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","volume":"7","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439\u2013R444","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"3726_CR36","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","volume":"55","author":"V Navarro-Comp\u00e1n","year":"2016","unstructured":"Navarro-Comp\u00e1n V, Plasencia-Rodr\u00edguez C, de Miguel E, Balsa A, Mart\u00edn-Mola E, Seoane-Mato D et al (2016) Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatol Oxf Engl. 55(7):1188\u20131194","journal-title":"Rheumatol Oxf Engl."},{"issue":"6","key":"3726_CR37","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/annrheumdis-2014-206616","volume":"74","author":"E Lie","year":"2015","unstructured":"Lie E, Kristensen LE, Forsblad-d\u2019Elia H, Zverkova-Sandstr\u00f6m T, Askling J, Jacobsson LT et al (2015) The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis 74(6):970\u2013978","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3726_CR38","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","volume":"69","author":"JL Nam","year":"2010","unstructured":"Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EMA et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69(6):976\u2013986","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3726_CR39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","volume":"73","author":"KM Fagerli","year":"2014","unstructured":"Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, R\u00f8devand E et al (2014) The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 73(1):132\u2013137","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3726_CR40","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/art.39691","volume":"68","author":"MJ Nissen","year":"2016","unstructured":"Nissen MJ, Ciurea A, Bernhard J, Tamborrini G, Mueller R, Weiss B et al (2016) The effect of comedication with a conventional synthetic disease-modifying antirheumatic drug on drug retention and clinical effectiveness of anti\u2013tumor necrosis factor therapy in patients with axial spondyloarthritis. Arthritis Rheumatol 68(9):2141\u20132150","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"3726_CR41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MAJ.0b013e3182514093","volume":"343","author":"JD Reveille","year":"2012","unstructured":"Reveille JD, Ximenes A, Ward MM (2012) Economic considerations of the treatment of ankylosing spondylitis. Am J Med Sci 343(5):371\u2013374","journal-title":"Am J Med Sci"},{"issue":"9766","key":"3726_CR42","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(10)61884-3","volume":"377","author":"AS Kumar","year":"2011","unstructured":"Kumar AS, Chen LC, Choudhury M, Ganju S, Mahajan V, Sinha A et al (2011) Financing health care for all: challenges and opportunities. Lancet 377(9766):668\u2013679","journal-title":"Lancet"},{"issue":"9764","key":"3726_CR43","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(10)61894-6","volume":"377","author":"Y Balarajan","year":"2011","unstructured":"Balarajan Y, Selvaraj S, Subramanian SV (2011) Health care and equity in India. Lancet 377(9764):505\u2013515","journal-title":"Lancet"},{"key":"3726_CR44","first-page":"1719","volume":"11","author":"O Elalouf","year":"2015","unstructured":"Elalouf O, Elkayam O (2015) Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis. Ther Clin Risk Manag 11:1719\u20131726","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"3726_CR45","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/rheumatology\/kem166","volume":"46","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatol Oxf Engl 46(9):1450\u20131453","journal-title":"Rheumatol Oxf Engl"},{"key":"3726_CR46","doi-asserted-by":"crossref","unstructured":"Maas F, Spoorenberg A, Brouwer E, Bos R, Efde M, Chaudhry RN, et al. Spinal Radiographic Progression in Patients with Ankylosing Spondylitis Treated with TNF-\u03b1 Blocking Therapy: A Prospective Longitudinal Observational Cohort Study. PLoS ONE [Internet]. 2015 Apr 16 [cited 2016 Dec 14];10(4). Available from: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4400173\/","DOI":"10.1371\/journal.pone.0122693"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3726-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3726-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3726-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T17:00:20Z","timestamp":1569517220000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3726-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,23]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["3726"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3726-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,23]]}}}